Inhibrx, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenue
License fee revenue
Grant revenue
Total revenue
Operating expenses:
Research and development
General and administrative
Abandoned offering costs
Total operating expenses

Loss from operations
Other income (expense):
Interest expense, net
Interest expense
Interest income
Other income (expense), net
Change in fair value of warrant liabilities
Change in fair value of derivative liabilities
Total other expense
Loss before provision for income taxes
Provision for income taxes
Loss from equity method investment
Net loss per share, basic and diluted (in dollars per share)
Weighted-average shares of common stock outstanding, basic and diluted (in shares)
Net loss
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)
Weighted-average shares of common stock outstanding, basic (in shares)
Weighted-average shares of common stock outstanding, diluted (in shares)

Comments